SHARE TICKER: GUBRA | NASDAQ COPENHAGEN

Gubra Conference Call to Discuss GUBamy Licensing Agreement with AbbVie

3 March 2025

Present from Gubra:

Henrik Blou, CEO

Louise S. Dalbøge, CSO

Kristian Borbos, CFO

gubra

SCIENCE OF CERTAINTY

Forward looking statements

Matters discussed in this presentation may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and that can be identified by words such as “believe“, “expect“, “anticipate“, “intends“, “estimate“, “will“, “may“, “continue“, “should“, and similar expressions. The absence of these words, however, does not mean that the statements are not forward-looking.

The forward-looking statements in this presentation are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.

The information, opinions and forward-looking statements contained in this presentation speak only as at its date and are subject to change without notice.

+

Partnership realizes full potential of GUBamy for the treatment of obesity

- Enables the incorporation of GUBamy, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for patients in need
- Accelerates GUBamy's robust development plan to optimize commercial potential
- Partnership marks AbbVie's entrance into the obesity field

An exclusive global license agreement with AbbVie

- Gubra grants AbbVie an exclusive global license to develop and commercialize GUBamy, a long-acting amylin analogue

- Deal terms:
  - Gubra will receive $350 million upfront
  - Gubra is also eligible to receive up to $1.875 billion in development, commercial and sales milestone payments
  - Tiered royalties on global net sales

- Combines Gubra's expertise in discovery, design and development of peptide-based drug candidates with AbbVie's clinical development expertise and global commercialization footprint
- The transaction closure is subject to regulatory approvals and other customary closing conditions.

GUBamy could be positioned as both an alternative and addition to incretin-based therapies

Extensive need for alternative therapies

GUBamy as stand-alone therapy

GUBamy as combination therapy

GUBamy holds potential to become the next generation weight management therapy

GUBamy

- Balanced receptor profile (AMYR and CTR)
- Long half-life (T½)
- Body weight loss alone and in combination
- Physical and chemical stable at neutral pH
- Very long patent exclusivity

SAD study results* – conclusions

1. GUBamy was well tolerated with adverse events being predominantly GI related, mild, and transient.
2. GUBamy had a favourable pharmacokinetic profile with a half-life of 11 days supporting once weekly dosing.
3. A single dose of GUBamy reduced body-weight dose dependently – the effect was sustained for the duration of the trial (6 weeks).
4. Mean body weight reduction in all high dose groups (3.5-6.0 mg) reached approx. 3% during the 6 weeks trial, whereas subjects in the placebo group gained approx. 1%.
5. The results support further development of GUBamy for a weight management indication.

*SAD results disclosed in Nov 2024

Ongoing Phase 1 Multiple Ascending Dose (MAD)



Part A
+ BMI 22-32 kg/m2
+ n=8 per cohort
+ 6 weeks treatment

Part B
+ BMI 27-35 kg/m^2
+ n=12 per cohort
+ 12 weeks treatment

MAD study design
+ Randomized
+ Double-blinded within cohorts
+ Placebo-controlled
+ Once weekly subcutaneous dosing
+ 52 subjects (males and females)
+ First subject (Dose 1) dosed in September 2024

Thank you for your attention

Gubra A/S
Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

Phone: +45 3152 2650
www.gubra.dk

Let's stay connected